Backs FY26 revenue view $46B-$47.5B consensus $47.12B. Sees FY gross margin 69%-70% and operating expenses $16.3B. The company continues to expect total Worldwide Eliquis revenues to increase in 2026, when compared to 2025, in the 10%-15% range.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers Squibb Posts Q1 2026 Results, Reaffirms Outlook
- Options Volatility and Implied Earnings Moves Today, April 30, 2026
- Notable companies reporting before tomorrow’s open
- BMY Upcoming Earnings Report: What to Expect?
- Options Volatility and Implied Earnings Moves This Week, April 27 – May 01, 2026